整合基因组与临床变量提升MDS向AML转化及预后预测
该研究分析437例中国新诊断MDS患者的遗传与临床病理特征,构建了基于骨髓原始细胞比例及KRAS、STAG2、TP53突变的AML转化预测模型,并建立经证实的OS和PFS预后模型,风险分层优于IPSS-R/M。
要点
- 骨髓原始细胞比例及KRAS、STAG2、TP53突变是MDS向AML转化的显著预测因素。
- 新模型将患者分为四组,风险分层优于IPSS-R/M。
核心结论
- 整合基因组与临床变量可改善MDS向AML转化及生存预后预测。
- 新模型风险分层优于IPSS-R/M。
研究设计与样本
- 研究纳入437例新诊断MDS患者,表征其遗传和临床病理特征。
- 开发AML转化预测模型,并建立和验证OS与PFS预后模型。
主要发现
- 骨髓原始细胞百分比、KRAS、STAG2和TP53突变是疾病进展的显著预测因素。
- OS模型纳入年龄、性别及TP53、NF1、SRSF2、CSF3R、ETV6、CEBPA、BCOR、TET2、JAK2和SF3B1突变。
- PFS模型纳入年龄、性别、骨髓原始细胞百分比及STAT3、TP53、NF1、CEBPA、ETV6、CALR、DNMT3A、IDH2、GATA2、BCOR、JAK2、TET2和SF3B1突变。
- 模型将患者分为预后良好、中间-1、中间-2和不良四个风险组。
关键数值与推荐
- MDS向AML转化风险为30%-40%。
- 风险分层组别:预后良好、中间-1、中间-2、不良。
临床怎么用
- 可基于骨髓原始细胞比例及KRAS、STAG2、TP53突变预测MDS向AML转化风险。
- 利用OS和PFS模型进行风险分层,辅助治疗策略制定。
局限性
- 研究队列为中国新诊断MDS患者,外推需谨慎。
- 模型验证细节未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) are heterogeneous stem cell disorders with a 30%-40% risk of transformation to acute myeloid leukaemia (AML). This study characterised the genetic and clinicopathological features of 437 newly diagnosed MDS patients. A predictive model for AML transformation was developed, which identified the bone marrow blast percentage, KRAS, STAG2 and TP53 mutations as significant predictors of disease progression. Novel prognostic models for overall survival (OS) and progression-free survival (PFS) were established and validated. The OS model incorporated age, sex and mutations in TP53, NF1, SRSF2, CSF3R, ETV6, CEBPA, BCOR, TET2, JAK2 and SF3B1. The PFS model incorporated age, sex, bone marrow blast percentage and mutations in STAT3, TP53, NF1, CEBPA, ETV6, CALR, DNMT3A, IDH2, GATA2, BCOR, JAK2, TET2 and SF3B1. These models stratify patients into favourable, intermediate-1, intermediate-2 and adverse risk groups, demonstrating superior risk stratification compared to the Revised/Molecular International Prognostic Scoring System (IPSS-R/M). This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.
引用
- Jin H, Guo Z, Zhu L, et al. Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. Br J Haematol. 2025. PMID: 41386566. doi:10.1111/bjh.70284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。